Form 4: TherapeuticsMD Director Collins Reports Stock Transactions
SEC Form 4 Filing
Director Cooper C. Collins reports the acquisition of 8,500 shares of TherapeuticsMD common stock through the settlement of restricted stock units.
Summary
- On February 18, 2025, Cooper C. Collins, a director of TherapeuticsMD, Inc., acquired 8,500 shares of common stock.
- The acquisition was a result of the settlement of restricted stock units (RSUs).
- The RSUs vested on July 17, 2024.
- The price per share for the transaction was $0.
- Following the transaction, Collins directly owns 60,516 shares of TherapeuticsMD common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Key Dates
| Date | Description |
|---|---|
| July 17, 2024 | Restricted Stock Units vested |
| February 18, 2025 | Acquisition of 8,500 shares of common stock through RSU settlement |
| February 20, 2025 | Date of signature for the Form 4 filing |
Keywords
TherapeuticsMD, Director, Collins, Stock, RSU, TXMD, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.